Review
Copyright ©2012 Baishideng Publishing Group Co.
World J Hepatol. May 27, 2012; 4(5): 158-168
Published online May 27, 2012. doi: 10.4254/wjh.v4.i5.158
Table 1 Immune dysfunction in cirrhotic patients
Natural barriersFragile, thin and/or edematous skin Alteration of gastrointestinal motility, mucosal permeability and bacterial flora ↑ Gastrointestinal mucosal ulcerations
Hepatic RES activityPortosystemic shunting Kupffer cells –↓ number, impaired function
Cellular defense mechanismsRES –↓ activation, ↓ chemotaxis, ↓ phagocytosis, ↓ production of pro-inflammatory cytokines PMN –↓ lifespan, ↓ intracellular killing activity, ↓ phagocytosis, ↓ chemotaxis
Serum factors↓ Complement levels (C3, C4, CH50) ↓ Opsonic activity ↓ Protein C activity
Iatrogenic and treatment-related factorsInvasive procedure and catheters Medications: immunosuppressive agents, proton pump inhibitors
Other compelling factorsMalnutrition Alcohol drinking